Eileen Handberg

Eileen Handberg, Ph.D., ARNP, BC, Director, CTSI Cardiovascular Clinical Research Unit

A large number of short-and long-term clinical trials are underway involving the use of new pharmacotherapeutic agents or new therapeutic strategies for the treatment of myocardial ischemia, hypertension, heart failure and arrhythmias. For example, we are part of an eleven-center NIH-sponsored trial, the Women’s Health Initiative (WHI), which includes hormone replacement and dietary modification trials to reduce heart disease and cancer in post-menopausal women. Several new compounds are in their early phase of clinical investigation for ischemia. They include nitric oxide donors, specific bradycardic agents and metabolic active agents. We are also evaluating the effects of various agents on coronary artery endothelial dysfunction. We are one of five centers in the NHLBI-sponsored Cardiovascular Cell Therapy Research Network along with Cleveland Clinic Lerner College of Medicine, Texas Heart Institute, Vanderbilt University Medical Center, and Minneapolis Heart Institute Foundation/University of Minnesota. These projects include use of cell therapy for acute myocardial infarction and congestive heart failure. We also have several other projects underway and a Training Core for cardiovascular cell therapy. These examples are provided to give an indication of some of the types of research in progress.


For additional information, please contact Dr. Handberg at 352-273-8944,